KR20120007059A - 4―（3―클로로―2―플루오로―아닐리노）―7―메톡시―6―［［1―（ｎ―메틸카르바모일메틸）―피페리딘―4―일］옥시］퀴나졸린의 제조 방법 - Google Patents

4―（3―클로로―2―플루오로―아닐리노）―7―메톡시―6―［［1―（ｎ―메틸카르바모일메틸）―피페리딘―4―일］옥시］퀴나졸린의 제조 방법 Download PDF

Info

Publication number
KR20120007059A
KR20120007059A KR1020117027878A KR20117027878A KR20120007059A KR 20120007059 A KR20120007059 A KR 20120007059A KR 1020117027878 A KR1020117027878 A KR 1020117027878A KR 20117027878 A KR20117027878 A KR 20117027878A KR 20120007059 A KR20120007059 A KR 20120007059A
Authority
KR
South Korea
Prior art keywords
compound
formula
chloro
acid
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117027878A
Other languages
English (en)
Korean (ko)
Inventor
카이 알리슨 보드만
올리버 로버트 쿠닝햄
윌리엄 군드라이
데이비드 더모트 패트릭 라판
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20120007059A publication Critical patent/KR20120007059A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020117027878A 2009-04-23 2010-04-22 4―（3―클로로―2―플루오로―아닐리노）―7―메톡시―6―［［1―（ｎ―메틸카르바모일메틸）―피페리딘―4―일］옥시］퀴나졸린의 제조 방법 Withdrawn KR20120007059A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17199409P 2009-04-23 2009-04-23
US61/171,994 2009-04-23

Publications (1)

Publication Number Publication Date
KR20120007059A true KR20120007059A (ko) 2012-01-19

Family

ID=42224659

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117027878A Withdrawn KR20120007059A (ko) 2009-04-23 2010-04-22 4―（3―클로로―2―플루오로―아닐리노）―7―메톡시―6―［［1―（ｎ―메틸카르바모일메틸）―피페리딘―4―일］옥시］퀴나졸린의 제조 방법

Country Status (14)

Country Link
US (1) US8450482B2 (cg-RX-API-DMAC10.html)
EP (1) EP2421827A2 (cg-RX-API-DMAC10.html)
JP (1) JP2012524769A (cg-RX-API-DMAC10.html)
KR (1) KR20120007059A (cg-RX-API-DMAC10.html)
CN (1) CN102459174A (cg-RX-API-DMAC10.html)
AR (1) AR076407A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010240717A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1013854A2 (cg-RX-API-DMAC10.html)
CA (1) CA2758610A1 (cg-RX-API-DMAC10.html)
IL (1) IL215388A0 (cg-RX-API-DMAC10.html)
MX (1) MX2011011177A (cg-RX-API-DMAC10.html)
SG (1) SG174893A1 (cg-RX-API-DMAC10.html)
TW (1) TW201041871A (cg-RX-API-DMAC10.html)
WO (1) WO2010122340A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
CN108503596A (zh) * 2018-03-14 2018-09-07 盐城师范学院 一种新的厄洛替尼及其中间体的制备方法
CN108440420A (zh) * 2018-03-22 2018-08-24 盐城师范学院 酪氨酸激酶抑制剂拉帕替尼及其关键中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
BRPI0414532B1 (pt) * 2003-09-19 2018-06-05 Astrazeneca Ab Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina
WO2005115145A2 (en) * 2004-05-20 2005-12-08 Wyeth Quinone substituted quinazoline and quinoline kinase inhibitors
WO2009138779A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
MX2010012442A (es) * 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.

Also Published As

Publication number Publication date
CA2758610A1 (en) 2010-10-28
JP2012524769A (ja) 2012-10-18
WO2010122340A2 (en) 2010-10-28
US8450482B2 (en) 2013-05-28
AR076407A1 (es) 2011-06-08
MX2011011177A (es) 2011-11-18
WO2010122340A3 (en) 2011-09-09
CN102459174A (zh) 2012-05-16
WO2010122340A8 (en) 2011-12-15
SG174893A1 (en) 2011-11-28
EP2421827A2 (en) 2012-02-29
US20120108814A1 (en) 2012-05-03
BRPI1013854A2 (pt) 2017-05-16
IL215388A0 (en) 2011-12-29
TW201041871A (en) 2010-12-01
AU2010240717A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
JP6889494B2 (ja) ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
JP6437820B2 (ja) キナゾリン誘導体、その製造方法、中間体、組成物及びその適用
JP6704422B2 (ja) キナゾリン誘導体の塩およびその製造方法
TWI443095B (zh) 新穎鹽
KR101378260B1 (ko) 세로토닌 및 노르에피네프린 재흡수 억제제
US8450482B2 (en) Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline
AU2016318700B2 (en) Crystalline form of androgen receptor inhibitor and preparation method thereof
JP4783738B2 (ja) 置換ジヒドロキナゾリンｉｉ
JP2002510625A (ja) Ｍｒｐ１の阻害方法
US8729130B2 (en) Methods of using novel solid forms of tacedinaline
EP3689861A1 (en) Optically active pyrrolidine compound and method for producing same
WO2012003413A1 (en) Novel solid forms of tacedinaline
CN102060875A (zh) 新型喹唑啉衍生物、制备方法和用途
CN103339124A (zh) 二(芳氨基)芳基化合物的制备方法及其合成中间体
CN103554091B (zh) 喹唑啉衍生物及其制备方法和用途
HU231012B1 (hu) Lapatinib sók
HK40014240A (en) Heteroarylphenoxy benzamide kappa opioid ligands
CZ20003687A3 (cs) Způsoby inhibice MRP1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid